In July 2025, the UK Government published the long-awaited NHS 10-year plan for England.
In a Viewpoint, authors identify key obstacles to implementing the plan & propose actions to improve implementation: http://spkl.io/6010AQz4s
Efficacy and safety of minocycline in patients with acute ischaemic stroke (EMPHASIS): a multicentre, double-blind, randomised controlled trial http://spkl.io/6013AtTWv
Tetanus, although preventable by a highly effective vaccine, continues to cause 30,000-50,000 deaths annually.
A recent Seminar explores the current state of tetanus, underscoring the importance of sustained immunisation efforts & improved access to care: http://spkl.io/6017AtoM5
Triple therapy inhaler reduces risk of severe asthma attacks and improves breathing in people with uncontrolled asthma, trial confirms.
Find out more in @LancetRespirMed: http://spkl.io/6011AtoM1
"Safety communication needs to reflect the best available evidence, not outdated or unsupported warnings."
Our latest Editorial—'Statin safety: when warnings outlive the evidence'.
Read now 👉 http://spkl.io/6012Ata02
On the cover this week, a major meta-analysis assesses the adverse effects attributed to statin therapy in product labels. 🏷️
The study found that almost all side effects on statin labels are not caused by statins. The authors call for the labels to be updated.
Read this & more: http://spkl.io/6015AtvkH
People with obesity at 70% higher risk of serious infection with one in ten infectious disease deaths globally potentially linked to obesity, study suggests.
Find out more 👉 http://spkl.io/6016AtTtj
📢 Join us tomorrow!
👉 Register now: https://hubs.li/Q03Ytgnx0
There's still time to register to join The Lancet Regional Health - Africa's editorial team as they share top tips on how to prepare your manuscript for publication in their journal.
#RegionalHealth #Africa
Arterial hypertension affects an estimated 25–30% of adults worldwide.
Innovative approaches are needed to improve hypertension care.
A new Therapeutics Review explores new drug therapies for hypertension: http://spkl.io/6012AtTNs
☀️ On the cover of @TheLancetInfDis June issue in time for European arbovirus season, the @PREPARE_EUROPE MERMAIDS-Arbo doublebill of papers with commentary now in print - thank you!
🦟 Full issue:
https://www.thelancet.com/journals/laninf/issue/vol25no6/PIIS1473-3099(25)X0006-2
🤒 Clinical outcomes:
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00655-8/
🦠 Serology diagnostic algorithm:
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00654-6/
🗣️ Commentary:
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00076-3/
@louise_sigfrid @LouellaMRK @siyu1000 @MarionKoopmans
Trachoma is the leading infectious cause of blindness worldwide.
In a new Seminar, Esmael Habtamu & colleagues provide an overview of the key clinical and public health features of trachoma.
Explore now ➡️ https://hubs.li/Q03nWybF0
A study in @TheLancetInfDis confirmed the safety & efficacy of single low-dose primaquine in reducing malaria transmission in young children & could support global #malaria elimination efforts & limit the spread of drug resistant #malaria
https://www.iddo.org/news/new-study-confirms-malaria-drug-safe-children-and-could-reduce-disease-spread
@TropMedOxford
In @TheLancetInfDis, MSF highlighted the urgent need for a ring vaccination strategy to curb the cholera outbreak in DRC and neighbouring countries, worsened by ongoing conflict. #Cholera #GlobalHealth #DRC 💉
https://shorturl.at/2hRzU
Now, there is a 2024 WHO Bacterial Priority Pathogens List 🆕
An article in @TheLancetInfDis details the processes involved in this important revision ⤵️ http://bit.ly/3EoCZUG
While little is known about the mysterious #Oropouche virus in Latin America, a number of deaths have been reported along with impacts on unborn babies. A #CharitéBerlin study has discovered that the pathogen is more widespread than previously thought. https://www.charite.de/en/service/press_reports/artikel/detail/a_mysterious_pathogen_oropouche_virus_more_common_in_latin_america_than_previously_thought
We were so happy to partner with participants on this decentralized, technology-enabled trial. Innovative way to do trials. I just wish the result had been better for patients. @VirusesImmunity @YaleMed @yalediscovers @TheLancetInfDis https://medicine.yale.edu/news-article/does-paxlovid-reduce-long-covid-symptoms-yale-led-trial-finds-out/
1/5 🔥 Hot off the press — PAXLC trial results now in @TheLancetInfDis （🇯🇵日本語解説付き）
After 3 years of dedicated work, we’re proud to share results from PAX LC: a fully decentralized, double-blind, placebo-controlled, FDA-authorized Phase 2 trial of Paxlovid (nirmatrelvir/ritonavir) for long COVID across 48 U.S. states (NCT05668091)
✅ 100 adults with long COVID
✅ Randomized 1:1 to Paxlovid or placebo (ritonavir only)
✅ 15-day oral treatment
🎯 Primary outcome: Change in PROMIS-29 PHSS at Day 28 from baseline
Here’s what we found—and why it matters. 🧵👇
Get your free copy here: https://www.sciencedirect.com/science/article/pii/S1473309925000738?dgcid=coauthor
1/5 🔥速報：PAX LC 試験の結果が @TheLancetInfDis に掲載されました！
3年にわたる設計と実施を経て、コロナ後遺症に対するパキロピッドの有効性と安全性を検証した**分散型・二重盲検・プラセボ対照・FDA承認の第2相試験「PAX LC」**の結果を報告します（米国48州対象）。
✅ コロナ後遺症の成人100名が参加
✅ パキロピッドまたはプラセボ（リトナビルのみ）に1:1で無作為化
✅ 経口治療を15日間
🎯 主要評価項目：ベースラインから28日目時点での PROMIS-29 PHSS の変化
ここから、試験結果とその意義を詳しくご紹介します🧵👇
@MitsuakiSawano @bornali_27 @CesarCaraballoC @rohan_khera @jspertus @VirusesImmunity @hmkyale
@YaleMed @YaleIMed @YaleCardiology @YaleCII
#PAXLC #LongCOVID #RCT #Paxlovid
Find our other related materials here:
http://ClinicalTrials.gov : https://clinicaltrials.gov/study/NCT05668091
PAXLC Design Paper: https://www.sciencedirect.com/science/article/pii/S0002934324002717?via%3Dihub
PAXLC Demographics Paper: https://www.medrxiv.org/content/10.1101/2024.11.25.24317941v1
We are hiring a Deputy Editor for The Lancet Regional Health – Southeast Asia
Find out more about the role here
https://lnkd.in/gBEyCJKB
@TheLancet
@GKangInd
@doctorsoumya
@WHOSEARO
@AnuragAgrawalMD
@swarup1972
@vivekkute
@combatstrokeSL
@lakshmivijayku1
Well done to my sister @AnjaSaso on her excellent RCT just published in @TheLancetInfDis looking at effect of #pertussis vaccine in pregnancy
Huge amount of work at @mrcunitgambia 🇬🇲
Proud brother!
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00072-6/fulltext?rss=yes
RESISTANCE IN TB AND HIV: Article we just wrote for the @TheLancetInfDis on a consequence of HIV global funding cuts that has not been discussed much -the development of drug resistance in HIV and TB
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00209-9/fulltext
Out now in @TheLancetInfDis our #SEMVAc study demonstrates that the MVA-BN vaccine (Imvanex/Jynneos) is safe & effective against #mpox, but a single dose does not sufficiently protect people living with #HIV.
Thank you @EMA_News for support.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00018-0/fulltext
Cholera has skyrocketed globally in recent years, linked to factors such as conflict, displacement, and climate change.
A lack of political commitment & investment in controlling cases has also contributed to its resurgence.
Read more in the latest news piece from @TheLancetInfDis ▶️
https://hubs.li/Q039pBC90
With cholera resurging in recent years, this letter by @SecGTFCC @TheLancetInfDis highlights the crucial principle of adaptive surveillance. It stresses that surveillance must be tailored to different epidemiological contexts, as outlined in their guidance
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2825%2900143-4/fulltext
Very pleased to share our latest paper in @TheLancetInfDis. This paper considers the complex issues of antimicrobials at the end-of-life, including nonclinical factors that must be navigated in the dying process. Thanks to @BillyRosaPhD for leading this!
https://www.sciencedirect.com/science/article/pii/S1473309924008326
🆕The absence of essential diagnostic & therapeutic tools is a crucial barrier to Zika virus preparedness & response.
A @TheLancetInfDis & Lancet Microbe Series outlines a comprehensive strategy to advance research, policy, & investment to address this: https://hubs.li/Q038m_VF0
Delighted to share my latest clinical case report published in @TheLancetInfDis from Fudan University, highlighting a case of mistaken identity—sinusitis mimicking meningioma!
Thanks to @FadenLab from @MassEyeAndEar @Harvard, the co-first author, for his invaluable guidance
In this editorial in @TheLancetInfDis with @ACasadevall1 , we show how SARS-CoV-2 evolution once again defeated an anti-Spike mAb (#sipavibart / #AZD3152) before it reached the marked.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00812-0/abstract
@bjarijn @ShohamTxID @jhDavidSullivan @manuelenicastri @hueso_thomas
💊Very happy to share our paper in @TheLancetInfDis on doxypep: hopes and fears for implementation .
😍This is a joint effort with @GilmoreJNurse ; Manik Kohli; @EdFTMxxx ; @benvyle; and Laia Ventura
👉Access here: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00077-5/fulltext
Europe needs a sustainably funded influenza research and response network - especially in the light of H5N1 and current developments in the US. Read our commentary in The Lancet ID:
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00068-4/abstract
With @wendybarclay11, @MarionKoopmans and many other colleagues.